Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Accounts Payables (2021 - 2025)

Universe Pharmaceuticals' Accounts Payables history spans 4 years, with the latest figure at $352.9 million for Q3 2024.

  • For Q3 2024, Accounts Payables rose 12912.11% year-over-year to $352.9 million; the TTM value through Sep 2024 reached $352.9 million, up 12912.11%, while the annual FY2024 figure was $352.9 million, 12912.11% up from the prior year.
  • Accounts Payables for Q3 2024 was $352.9 million at Universe Pharmaceuticals, up from $2.7 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $352.9 million in Q3 2024 and bottomed at $2.7 million in Q3 2023.
  • The 4-year median for Accounts Payables is $4.2 million (2021), against an average of $91.0 million.
  • The largest annual shift saw Accounts Payables plummeted 42.09% in 2022 before it surged 12912.11% in 2024.
  • A 4-year view of Accounts Payables shows it stood at $5.3 million in 2021, then tumbled by 42.09% to $3.1 million in 2022, then decreased by 11.82% to $2.7 million in 2023, then soared by 12912.11% to $352.9 million in 2024.
  • Per Business Quant, the three most recent readings for UPC's Accounts Payables are $352.9 million (Q3 2024), $2.7 million (Q3 2023), and $3.1 million (Q3 2022).